BioTuesdays

Category - Markets

Verastem

Roth starts Verastem at buy; PT $12

Roth Capital Partners launched coverage of Verastem (NASDAQ:VSTM) with a “buy” rating and $12 price target. The stock closed at $3.66 on Nov. 29. Analyst Dr. Jotin Marango writes that his qualitative and quantitative...

Arcturus Logo

Ladenburg starts Arcturus at buy; PT $22

Ladenburg Thalmann initiated coverage of Arcturus Therapeutics (NASDAQ:ARCT) with a “buy” rating and $22 share price target. The stock closed at $8.71 on Nov. 28. Arcturus has developed a novel biodegradable lipid...

Viking Therapeutics Logo

Maxim ups Viking Therapeutics PT to $8

Maxim Group raised its price target for Viking Therapeutics (NASDAQ:VKTX) to $8 from $5 after the company announced results of a Phase 2 hip fracture study of its VK5211 compound. The stock was changing hands at $3.07...

Spero Therapeutics

Stifel starts Spero Therapeutics at buy; PT $26

Stifel initiated coverage of Spero Therapeutics (NASDAQ:SPRO) with a “buy” rating and $26 price target. The stock closed at $13.86 on Nov. 24. “We believe Spero’s wholly-owned product pipeline of novel antibiotics –...

Profound Medical Logo

CIBC starts Profound Medical at OP, PT $3.50

CIBC World Markets initiated coverage of Profound Medical (TSXV:PRN; OTCQX:PRFMF) with an “outperformer” rating and 12-to-18-month price target of $3.50. The stock closed at 85 cents on Nov. 15. Analyst Prakash Gowd...

Mirati Therapeutics

Leerink ups Mirati Therapeutics OP; PT $20

Leering upgraded Mirati Therapeutics (NASDAQ:MRTX) to “outperform” from “market perform” and raised its price target to $20 from $15, after the company re-prioritized its pipeline programs. The stock closed at $15.50 on...

GTX

Stifel starts GTx at buy; PT $16

Stifel initiated coverage of GTx (NASDAQ:GTXI) a “buy” rating and $16 price target. The stock closed at $7.51 on Nov. 8. “We believe the Street is overlooking blockbuster potential for lead pipeline asset, enobosarm, in...

IRIDEX

Roth resumes coverage of IRIDEX at buy, PT $13

Roth Capital Partners resumed coverage of IRIDEX (NASDAQ:IRIX) with a “buy” rating and $13 price target after the company reported modest upside to Roth’s prior revenue targets for the third quarter. “Further, the...